Recursion Executive and Leadership Team

Najat Khan, the Chief Executive Officer, President & Member, Board of Directors at Recursion, directs the overarching strategic vision for the organization. Khan architects the integration of machine learning and biological data to accelerate drug discovery pipelines. By overseeing the Recursion Operating System, the Chief Executive Officer ensures the company maintains a competitive edge in the biotechnology sector. This leadership role involves constant collaboration with the Board of Directors to align research initiatives with long-term commercial goals. Najat Khan drives the expansion of the company's proprietary datasets, which currently support large-scale industrialization of pharmaceutical research. Through rigorous oversight of internal automation and engineering teams, the Chief Executive Officer maintains operational excellence. Ultimately, Khan secures the necessary resources to navigate complex biological landscapes, ensuring the company remains at the forefront of clinical-stage innovation while delivering value to stakeholders across North American and international markets.

Madeleine Lyman, the Executive Business Partner To Ben Taylor. Chief Financial Officer and Sid Jain at Recursion, manages critical financial workflows and executive alignment. Lyman coordinates complex operational logistics between the finance department and senior leadership to ensure fiscal discipline across all research projects. By streamlining communication channels, the Executive Business Partner To Ben Taylor. Chief Financial Officer and Sid Jain optimizes resource allocation for the Recursion Map software development. This role requires precise management of budgetary constraints while supporting the rapid scaling of biological data infrastructure. Madeleine Lyman facilitates high-level decision-making processes that directly impact the company's ability to fund clinical-stage trials. Through meticulous oversight of administrative and financial reporting, the Executive Business Partner To Ben Taylor. Chief Financial Officer and Sid Jain maintains organizational stability. Lyman ensures that financial strategies remain synchronized with the broader mission of decoding biology, thereby supporting the company's growth trajectory within the competitive biotechnology landscape.

Vicki Goodman, the Chief Medical Officer at Recursion, oversees the clinical development strategy and regulatory pathways for the company's drug pipeline. Goodman translates complex biological insights derived from the Recursion Map into actionable clinical trial designs. By directing the medical affairs team, the Chief Medical Officer ensures that all research adheres to rigorous safety and efficacy standards. This leadership role involves close coordination with the R&D department to validate findings from the company's proprietary biological datasets. Vicki Goodman drives the clinical progression of therapeutic candidates, ensuring alignment with global health regulations. Through strategic oversight of patient-centric initiatives, the Chief Medical Officer impacts the company's ability to bring innovative treatments to market. Goodman manages the interface between computational biology and clinical application, ensuring that technological advancements directly benefit patient populations. Ultimately, the Chief Medical Officer secures the scientific integrity of the company's clinical-stage portfolio while navigating the complexities of modern drug development.

Ryan Kelly, the Chief Communications Officer & Leadership Executive & Team Member at Recursion, manages the company's public narrative and stakeholder engagement strategies. Kelly architects communication frameworks that articulate the value of the Recursion Operating System to investors, partners, and the broader scientific community. By overseeing internal and external messaging, the Chief Communications Officer & Leadership Executive & Team Member ensures consistent alignment with the company's mission to industrialize drug discovery. This role involves coordinating with the executive team to translate complex technical milestones into clear, impactful narratives. Ryan Kelly drives the company's reputation management across global markets, ensuring that the brand remains synonymous with innovation in biotechnology. Through strategic oversight of corporate communications, the Chief Communications Officer & Leadership Executive & Team Member supports the company's efforts to attract top-tier talent and capital. Kelly maintains the integrity of the company's public image, ensuring that all messaging reflects the core commitment to decoding biology for the benefit of patients.